Public market insider buying at Medicenna Therapeutics (MDNA)

Public market insider buying at Medicenna Therapeutics (T:MDNA)

Albert George Beraldo, a Director, acquired 100,000 Common Shares on a direct ownership basis at prices ranging from $1.136 to $1.179 between October 4th, 2022 and October 11th, 2022. This represents a $115,085 investment into the company's shares and an account share holdings change of 44.4%.

Medicenna Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Medicenna Therapeutics Corp. is a clinical stage immunotherapy company. The Company is primarily engaged in the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its Bi-functional SuperKine ImmunoTherapies (BiSKITs) platform is designed to enable the ability of Superkines to treat immunologically cold tumors. The Company's product candidate MDNA55, is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a fatal form of brain cancer. MDNA11, an IL-2 Superkine that has been fused with human recombinant albumin. The Company has not earned any revenues from its products.